keyword
MENU ▼
Read by QxMD icon Read
search

Relapsed diffuse large b cell lymphoma

keyword
https://www.readbyqxmd.com/read/29314151/comparison-of-ebv-positive-mucocutaneous-ulcer-ebvmcu-associated-with-treated-lymphoma-or-methotrexate-in-japan
#1
Teerada Daroontum, Kei Kohno, Ahmed E Eladl, Akira Satou, Ayako Sakakibara, Shoichi Matsukage, Naoki Yakushiji, Charin Ya-In, Shigeo Nakamura, Naoko Asano, Seiichi Kato
AIMS: The present study compared treated lymphoma-associated EBV-positive mucocutaneous ulcer (EBVMCU) and methotrexate (MTX)-associated EBVMCU. METHODS AND RESULTS: Of a series of 15 Japanese patients (11 women, 4 men; median age 74 years, range 35-84 years). 7 received MTX for autoimmune disease and 8 developed EBVMCU after treatment of malignant lymphoma (diffuse large B-cell lymphoma [n=4] without EBV association, adult T-cell leukaemia/lymphoma [n=2], angioimmunoblastic T-cell lymphoma [n=1], and follicular lymphoma [n=1])...
January 4, 2018: Histopathology
https://www.readbyqxmd.com/read/29310838/a-leukemic-double-hit-follicular-lymphoma-associated-with-a-complex-variant-translocation-t-8-14-18-q24-q32-q21-involving-bcl2-myc-and-igh
#2
Daisuke Minakata, Kazuya Sato, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kiyomi Mashima, Kento Umino, Hirofumi Nakano, Ryoko Yamasaki, Kaoru Morita, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Kaoru Hatano, Iekuni Oh, Shin-Ichiro Fujiwara, Ken Ohmine, Hirotoshi Kawata, Kazuo Muroi, Ikuo Miura, Yoshinobu Kanda
Double-hit lymphoma (DHL) is defined as lymphoma with concurrent BCL2 and MYC translocations. While the most common histological subtype of DHL is diffuse large B-cell lymphoma, the present patient had leukemic follicular lymphoma (FL). A 52-year-old man was admitted to our hospital due to general fatigue and cervical and inguinal lymph node swelling. The patient was leukemic and the pathological diagnosis of the inguinal lymph node was FL grade 1. Chromosomal analysis revealed a complex karyotype including a rare three-way translocation t(8;14;18)(q24;q32;q21) involving the BCL2, MYC, and IGH genes...
January 2018: Cancer Genetics
https://www.readbyqxmd.com/read/29306309/-intravitreal-rituximab-for-the-treatment-of-intraocular-relapse-of-non-hodgkin-s-lymphoma
#3
Eva Fernández Cañabate, Sonia Fernández-Cañabate
CLINICAL CASE: A 58-year-old woman with intraocular relapse of a diffuse large B cell lymphoma. Weekly intravitreal rituximab (1 mg/0.1 ml) for 4 weeks were  administered. 12 months after the last intravitreal rituximab dose, signs and  symptoms of lymphomas or adverse reactions associated with intravitreal Rituximab  administration were not observed. DISCUSSION: Intravitreal rituximab is an effective and safe treatment of intravitreal  lymphoma, by inducing complete remission; it could be a good alternative to other  therapeutic options with greater number of serious complications...
January 1, 2018: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/29290192/demographics-and-outome-in-paediatric-non-hodgkin-lymphoma-single-centre-experience-at-the-children-hospital-lahore-pakistan
#4
Mahwish Faizan, Saadia Anwar, Safia Khan
OBJECTIVE: To describe the patient demographics and outcome analysis in paediatric non-Hodgkin lymphoma (NHL) patients. STUDY DESIGN: An observational study. PLACE AND DURATION OF STUDY: The Hematology/Oncology Unit of The Children's Hospital and Institute of Child Health, Lahore, from January 2012 till December 2014. METHODOLOGY: Demographics including age, gender, histopathology, stage and outcome data, in biopsy proven NHL patients were analyzed...
January 2018: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/29284757/autologous-stem-cell-transplantation-in-elderly-lymphoma-patients-in-their-70s-outcomes-and-analysis
#5
Lova Sun, Shuli Li, Areej El-Jawahri, Philippe Armand, Bimalangshu R Dey, David C Fisher, Eric D Jacobsen, Caron A Jacobson, Ann S LaCasce, Steven L McAfee, Thomas R Spitzer, Yi-Bin Chen, Zachariah DeFilipp
BACKGROUND: High-dose chemotherapy and autologous stem cell transplantation (ASCT) can offer durable remission in many patients with relapsed or high-risk lymphoma. However, elderly patients are often not considered ASCT candidates based on age alone. SUBJECTS, MATERIALS, AND METHODS: A retrospective analysis of patients ≥70 years of age with a diagnosis of Hodgkin or non-Hodgkin lymphoma receiving ASCT between 2000 and 2016 at two partner institutions was performed...
December 28, 2017: Oncologist
https://www.readbyqxmd.com/read/29278676/utility-of-routine-surveillance-imaging-for-diffuse-large-b-cell-lymphoma-post-autologous-transplant-a-single-center-experience
#6
Ghulam Rehman Mohyuddin, Ashley Elizabeth Clark, John Roller, Leyla Shune, Tara Lin, Neil Dunavin, Ajoy Dias, Siddhartha Ganguly, Sunil Abhyankar, Joseph McGuirk, Anurag Singh
Surveillance scans after autologous stem cell transplant (auto-HCT) for patients with relapsed/refractory (RR) diffuse large B Cell lymphoma (DLBCL) have no proven survival benefit. We studied survival differences among patients with RR DLBCL post auto-HCT whose recurrences were detected clinically versus with routine surveillance imaging. Among the 139 patients with RR DLBCL that underwent auto-HCT from 2000 to 2014 at our institution, 37 relapsed: 21 clinical and 16 radiological. The median time to progression was 167 days for the clinical cohort and 565 days for the radiological cohort (p = 0...
December 19, 2017: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29251015/prognostic-impact-of-activation-induced-cytidine-deaminase-expression-for-patients-with-diffuse-large-b-cell-lymphoma
#7
Hiroshi Arima, Masakazu Fujimoto, Momoko Nishikori, Toshiyuki Kitano, Wataru Kishimoto, Masakatsu Hishizawa, Tadakazu Kondo, Kouhei Yamashita, Masahiro Hirata, Hironori Haga, Akifumi Takaori-Kondo
Activation-induced cytidine deaminase (AID) plays important roles in the development of diffuse large B-cell lymphoma (DLBCL); however, its prognostic value remains controversial. Here, we evaluated AID expression in 71 DLBCL patients treated with R-CHOP by immunohistochemistry and investigated its prognostic significance. AID expression was detected in 40.8% of DLBCL samples and associated with IRF4 expression. Notably, AID expression correlated with shorter progression-free survival and overall survival for patients with high (3-5) international prognostic index (IPI) score...
December 18, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29247018/value-in-using-car-t-cells-for-dlbcl
#8
(no author information available yet)
The phase II JULIET trial suggests that the CD19-targeting CAR T-cell therapy tisagenlecleucel produces durable responses in patients with relapsed and refractory diffuse large B-cell lymphoma. Three months after the therapy, 32% of the patients showed complete responses and 6% showed partial responses. After 6 months, those rates were 30% and 7%.
December 15, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29245897/comparative-analysis-of-primary-versus-relapse-refractory-dlbcl-identifies-shifts-in-mutation-spectrum
#9
Danielle M Greenawalt, Winnie S Liang, Sakina Saif, Justin Johnson, Petar Todorov, Austin Dulak, Daniel Enriquez, Rebecca Halperin, Ambar Ahmed, Vladislav Saveliev, John Carpten, David Craig, J Carl Barrett, Brian Dougherty, Michael Zinda, Stephen Fawell, Jonathan R Dry, Kate Byth
Current understanding of the mutation spectrum of relapsed/refractory (RR) tumors is limited. We performed whole exome sequencing (WES) on 47 diffuse large B cell lymphoma (DLBCL) tumors that persisted after R-CHOP treatment, 8 matched to primary biopsies. We compared genomic alterations from the RR cohort against two treatment-naïve DLBCL cohorts (n=112). While the overall number and types of mutations did not differ significantly, we identified frequency changes in DLBCL driver genes. The overall frequency of MYD88 mutant samples increased (12% to 19%), but we noted a decrease in p...
November 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/29242506/micrornas-regulate-key-cell-survival-pathways-and-mediate-chemosensitivity-during-progression-of-diffuse-large-b-cell-lymphoma
#10
Suvi-Katri Leivonen, Katherine Icay, Kirsi Jäntti, Ilari Siren, Chengyu Liu, Amjad Alkodsi, Alejandra Cervera, Maja Ludvigsen, Stephen Jacques Hamilton-Dutoit, Francesco d'Amore, Marja-Liisa Karjalainen-Lindsberg, Jan Delabie, Harald Holte, Rainer Lehtonen, Sampsa Hautaniemi, Sirpa Leppä
Despite better therapeutic options and improved survival of diffuse large B-cell lymphoma (DLBCL), 30-40% of the patients experience relapse or have primary refractory disease with a dismal prognosis. To identify biological correlates for treatment resistance, we profiled microRNAs (miRNAs) of matched primary and relapsed DLBCL by next-generation sequencing. Altogether 492 miRNAs were expressed in the DLBCL samples. Thirteen miRNAs showed significant differential expression between primary and relapse specimen pairs...
December 15, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/29234945/clinical-significance-and-functional-validation-of-inorganic-pyrophosphatase-in-diffuse-large-b-cell-lymphoma-in-humans
#11
Limei Li, Aruna, Dehong Luo, Arong Jin
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma, displays marked heterogeneity. Although it is usually curable, 30-40% of patients die within 1-2 years due to refractory treatment or cancer relapse. In different types of cancer in humans, inorganic pyrophosphatase (PPA1) is deregulated, thereby contributing to tumorigenesis by supplying the tumor with an enormous energy source. However, the role of PPA1 in DLBCL is still unclear. Here, we analized PPA1 in 65 patients with DLBCL and 20 patients with reactive hyperplasia of the lymph nodes (control)...
December 12, 2017: Cytotechnology
https://www.readbyqxmd.com/read/29228580/posttransplant-lymphoproliferative-disorders-in-kidney-transplant-recipients-a-retrospective-cohort-analysis-over-two-decades-in-hong-kong
#12
Chi Yuen Cheung, Maggie Kam Man Ma, Ka Foon Chau, Wai Leung Chak, Sydney Chi Wai Tang
Objective: To characterize the posttransplant lymphoproliferative disorders (PTLD) including the Epstein-Barr virus (EBV) status, histological subgroups, site of occurrence and the clinical outcome in the Chinese kidney transplant recipients. Methods: A retrospective cohort study of 1, 227 adult kidney transplant recipients who were followed up in two transplant centers in Hong Kong over two decades. Results: 23 (1.9%) patients developed PTLD...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29226764/chimeric-antigen-receptor-t-cells-in-refractory-b-cell-lymphomas
#13
Stephen J Schuster, Jakub Svoboda, Elise A Chong, Sunita D Nasta, Anthony R Mato, Özlem Anak, Jennifer L Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj, Daniel Landsburg, Mariusz Wasik, Bruce L Levine, Simon F Lacey, Jan J Melenhorst, David L Porter, Carl H June
Background Patients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory to or that relapses after immunochemotherapy and transplantation have a poor prognosis. High response rates have been reported with the use of T cells modified by chimeric antigen receptor (CAR) that target CD19 in B-cell cancers, although data regarding B-cell lymphomas are limited. Methods We used autologous T cells that express a CD19-directed CAR (CTL019) to treat patients with diffuse large B-cell lymphoma or follicular lymphoma that had relapsed or was refractory to previous treatments...
December 10, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29222307/secondary-cns-relapse-in-diffuse-large-b-cell-lymphoma-defining-high-risk-patients-and-optimization-of-prophylaxis-strategies
#14
REVIEW
Kerry J Savage
Despite improvement in survival in diffuse large B-cell lymphoma (DLBCL) with the introduction of rituximab, central nervous system (CNS) relapse continues to represent a clinical challenge. A number of studies have evaluated clinical risk factors in an attempt to identify high-risk patients to direct CNS staging investigations and consider prophylaxis strategies. The CNS International Prognostic Index is a robust and reproducible risk model that can identity patients at high risk of CNS relapse, but its specificity remains limited...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29207605/vegf121-is-predictor-for-survival-in-activated-b-cell-like-diffuse-large-b-cell-lymphoma-and-is-related-to-an-immune-response-gene-signature-conserved-in-cancers
#15
Julien Broséus, Samia Mourah, Gérard Ramstein, Sophie Bernard, Nicolas Mounier, Wendy Cuccuini, Philippe Gaulard, Christian Gisselbrecht, Josette Brière, Rémi Houlgatte, Catherine Thieblemont
Tumor microenvironment including endothelial and immune cells plays a crucial role in tumor progression and has been shown to dramatically influence cancer survival. In this study, we investigated the clinical relevance of the gene expression of key mediators of angiogenesis, VEGF isoforms 121, 165, and 189, and their receptors (VEGFR-1 and R-2) in a cohort of patients (n = 37) with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) from the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL)...
October 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/29202455/a-simple-clinically-relevant-therapeutic-vaccine-shows-long-term-protection-in-an-aggressive-delayed-treatment-b-lymphoma-model
#16
Pallab Pradhan, Jardin Leleux, Jiaying Liu, Krishnendu Roy
Despite initial remission after successful treatments, B lymphoma patients often encounter relapses and resistance causing high mortality. Thus, there is a need to develop therapies that prevent relapse by providing long-term protection and, ultimately, lead to functional cure. In this study, our goal was to develop a simple, clinically relevant, and easily translatable therapeutic vaccine that provides durable immune protection against aggressive B cell lymphoma and identify critical immune biomarkers that are predictive of long-term survival...
November 16, 2017: JCI Insight
https://www.readbyqxmd.com/read/29198127/immunohistochemical-investigation-of-p16-p53-and-ki-67-s-prognostic-values-in-diffuse-large-b-cell-lymphomas
#17
M Baran, O Canoz, H Altuntas, S Sivgin, M Cetin, A Yay, S Ketenci
AIM: The aim of this study is to determine the immunohistochemical properties of Ki-67, P53 expression and loss of P16, and to assess their relationship with both clinical parameters and patient survival in DLBCL. METHOD: Forty patients, diagnosed at the Pathology Department of our institute with nodal DLBCL were selected as the study group. The relationship between P16, P53, Ki-67 expressions and clinical and laboratory parameters like age, gender, performance status, Eastern Cooperative Oncology Group (ECOG), clinical stage, presence of B-symptoms, bone marrow involvement, International Prognostic Index (IPI) score, lactate dehydrogenase (LDH) level, extranodal extension, relapse, C-reactive protein (CRP), sedimentation, number of leukocytes in patients and patient survival were then statistically evaluated...
2017: Bratislavské Lekárske Listy
https://www.readbyqxmd.com/read/29196178/long-term-remissions-of-patients-with-follicular-lymphoma-grade-3-treated-with-r-chop
#18
Paolo Strati, Nathan Fowler, Sergio Pina-Oviedo, L Jeffrey Medeiros, Michael J Overman, Jorge E Romaguera, Loretta Nastoupil, Michael Wang, Fredrick B Hagemeister, Alma Rodriguez, Yasuhiro Oki, Jason Westin, Francesco Turturro, Sattva S Neelapu, Luis Fayad
BACKGROUND: The optimal management of patients with follicular lymphoma Grade 3 (FLG3) is controversial. PATIENTS AND METHODS: This is a case series of 45 patients with FLG3 treated with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and observed for an extended time interval. RESULTS: The overall response rate was 100% and the median progression-free survival (PFS) has not been reached, with a 3-year PFS of 70%; 14 (31%) patients relapsed, nearly all within 3 years...
November 14, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29195613/interim-fdg-pet-imaging-in-lymphoma
#19
REVIEW
Andrea Gallamini, Colette Zwarthoed
In the present article, the authors reviewed the rationale of FDG-PET/CT performed at an interim time point during therapy (iPET), focusing on the transition from standard, anatomical assessment of tumor shrinkage with CT to document a chemotherapy response, to the use of functional imaging with PET to assess chemosensitivity of the individual tumor. The prognostic or predictive role of iPET in different lymphoma subsets has been reviewed, with particular emphasis on early and advanced-stage Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, extranodal natural killer/T-cell lymphoma, and primary mediastinal B-cell lymphoma...
January 2018: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/29174982/cd4-t-cell-mediated-cytotoxicity-is-associated-with-mhc-class-ii-expression-on-malignant-cd19-b-cells-in-diffuse-large-b-cell-lymphoma
#20
Yong Zhou, Jie Zha, Zhijuan Lin, Zhihong Fang, Hanyan Zeng, Jintao Zhao, Yiming Luo, Zhifeng Li, Bing Xu
Diffuse large B cell lymphoma (DLBCL) is a common B cell malignancy with approximately 30% of patients present relapsed or refractory disease after first-line therapy. Research of further treatment options is needed. Cytotoxic CD4+ T cells express cytolytic molecules and have potential antitumor function. Here, we showed that the CD19+ cells from DLBCL patients presented significantly reduced expression of MHC II molecules than those from healthy controls. Three years after the first-line treatment, patients that presented relapsed disease had significantly lower MHC II expression on their CD19+ cells than patients who did not show recurrence...
November 22, 2017: Experimental Cell Research
keyword
keyword
101126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"